We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
151
Squarepoint
New York
$764K -$1.65M -38,540 -67%
TC
152
TwinBeech Capital
New York
$732K +$761K +17,813 New
Zurich Cantonal Bank
153
Zurich Cantonal Bank
Switzerland
$731K +$3.97K +93 +0.5%
Teacher Retirement System of Texas
154
Teacher Retirement System of Texas
Texas
$669K -$7.43K -174 -1%
SG Americas Securities
155
SG Americas Securities
New York
$653K +$679K +15,898 New
GCP
156
GSA Capital Partners
United Kingdom
$640K +$215K +5,026 +48%
EAM
157
Erste Asset Management
Austria
$622K – – –
Capital Fund Management (CFM)
158
Capital Fund Management (CFM)
France
$616K +$640K +14,996 New
EGM
159
Engineers Gate Manager
New York
$590K -$2.8M -65,505 -82%
TRCT
160
Tower Research Capital (TRC)
New York
$588K +$548K +12,841 +878%
RJFSA
161
Raymond James Financial Services Advisors
Florida
$585K -$60.1K -1,407 -9%
WC
162
Woodstock Corp
Massachusetts
$570K +$117K +2,747 +25%
TI
163
Tidal Investments
Wisconsin
$562K +$584K +13,676 New
Natixis Advisors
164
Natixis Advisors
Massachusetts
$554K -$9.31K -218 -2%
DnB Asset Management
165
DnB Asset Management
Norway
$532K +$125K +2,921 +29%
P
166
Pitcairn
Pennsylvania
$495K +$174K +4,083 +51%
Ameriprise
167
Ameriprise
Minnesota
$484K -$80.7K -1,889 -14%
SEC
168
Seven Eight Capital
New York
$483K -$1.53M -35,796 -75%
ProShare Advisors
169
ProShare Advisors
Maryland
$458K +$216K +5,068 +83%
X
170
Xponance
Pennsylvania
$456K +$54.6K +1,279 +13%
Group One Trading
171
Group One Trading
Illinois
$430K +$57K +1,335 +15%
Allianz Asset Management
172
Allianz Asset Management
Germany
$427K -$120K -2,800 -21%
Principal Financial Group
173
Principal Financial Group
Iowa
$423K -$243K -5,687 -36%
JFG
174
Jefferies Financial Group
New York
$421K +$438K +10,250 New
Victory Capital Management
175
Victory Capital Management
Texas
$414K -$4.06K -95 -0.9%
5 6
7
8 9

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.